9 September 2016 - Deborah Wilkes
Archived
Valeant Pharmaceuticals International is focusing on divesting non-core assets but will "never say never" to selling core assets like the Bausch + Lomb eyecare business, according to chairman and chief executive officer Joseph Papa.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.